-
Abstract Number: 854
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
-
Abstract Number: 855
Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?
-
Abstract Number: 856
MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
-
Abstract Number: 857
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
-
Abstract Number: 858
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE
-
Abstract Number: 859
Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
-
Abstract Number: 860
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
-
Abstract Number: 861
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
-
Abstract Number: 862
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study
-
Abstract Number: 863
Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial
-
Abstract Number: 864
Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
-
Abstract Number: 865
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
-
Abstract Number: 866
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease
-
Abstract Number: 867
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
-
Abstract Number: 868
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
- « Previous Page
- 1
- …
- 58
- 59
- 60
- 61
- 62
- …
- 198
- Next Page »